Corporate Ads

Today's air-permit approval and immediate Eagle Springs restart mark a major operational milestone, while 5,000-barrel-per-day capacity, 15,000 barrels of crude inventory, Nevada oil-development plans and a tightening Western refining market put Sky...

Cycurion, Inc. (N A S D A Q: CYCU) Expands From Government Cybersecurity Into Public Safety, Healthcare, AI, Fleet Analytics and Commercial Markets as Q2 Margins Surge Nearly 5X and Management Authorizes $500K Share Repurchases

$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent...

Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus

New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets.

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S.